Sealants/Glues, Hemostats, Other Wound Closure Markets, Size and Growth

Products in wound closure include sutures/staples, tapes, vascular closure devices, surgical hemostats, and surgical sealants/glues.

Wound types have not changed over history, with a slight exception being the emergence (several decades ago) of femoral punctures associated with catheterization procedures. But what has changed, and what continues to evolve, is the practice of closing those wounds. Sutures, staples and tapes are a mainstay of medical practice, representing uncomplicated methods to secure wounds. And while innovators continue to change the form and function of these products to improve performance, the more recently introduced surgical hemostats, vascular closure, and surgical sealants/glues have seized significant shares of wound closure caseload and are growing marginally faster than sutures/staples and tapes. The result is and will be an erosion of traditional wound closure technology shares.

Below is illustrated the size/growth of segments in the global wound closure market.

Screen Shot 2015-04-13 at 7.05.33 AM
Source: MedMarket Diligence, LLC; “Worldwide Surgical Sealants, Glues, and Wound Closure Markets, 2013-2018″, Report #S192.

Surgical Glues, Sealants, Hemostats and Wound Closure Worldwide Markets

Acute wounds have long represented a core focus of healthcare, one that manufacturers have been steadily changing through innovative new technologies. MedMarket Diligence’s global report on wound closure markets reveals the dynamics of this change, detailing the clinical practices, products, technologies, companies and the resulting current and forecast markets.

PRLogApril 7, 2015MISSION VIEJO, Calif.The products and technologies focused on the management of acute wounds, encompassing hemostasis, closure and sealing represent a significant, growing segment of the total medical device market. The global market for surgical sealants, glues, and wound closure devices reached over $10.8 billion in 2014 and is forecast to increase to about $14 billion in 2018, exhibiting an overall compound annual growth rate (2014-2018) of 7.0%, according to the latest global report on wound closure and related products, published by MedMarket Diligence.

“We have tracked this market as manufacturers introduced novel wound sealing and closure technologies intended to integrate with one of the highest volume areas of healthcare,” says Patrick Driscoll, President of MedMarket Diligence. According to Driscoll, the level of innovation has been remarkable — from the advent of fibrin glues, to the continued evolution of sutures and staples, to the emergence of products working alone or in tandem to achieve better outcomes in a cost sensitive climate.This market is comprised of sutures/staples, vascular closure devices, surgical tapes, surgical hemostats, and surgical sealants and glues. There are well over 100 companies active in the marketing and development of these products, with the associated technologies running the gamut from devices to biologics to synthetics.

Wound closure has become a clinical practice that is rapidly evolving from what was once simple suturing or taping wounds to more sophisticated procedures that ensure rapid cessation of blood loss, prompt closure, strong adhesion of wound edges, tight sealing, reduced scarring, reduced risk of infection and more rapid healing — all accomplished largely with existing surgeon skills and with reasonable costs for healthcare payers and margins for manufacturers.

Surgical sealants and glues are expected to demonstrate the highest growth rate over the forecast period, but the largest segment in terms of revenues is the sutures and staples market, which comprise about half of the worldwide total. Hemostats represent the next largest segment, followed by surgical sealants and glues, tapes, and vascular closure devices.

The market leaders in this area are Johnson & Johnson, Covidien, B. Braun, and 3M, but market shares have proven to be fluid as innovations from hundreds of competitors are gaining and expanding footholds in the big companies’ territories.

The MedMarket Diligence report, “Worldwide Surgical Sealants, Glues, and Wound Closure Markets, 2013-2018“, provides specific forecasts and shares of the worldwide market by segment for Americas (detail for U.S., Rest of North America and Latin America), Europe (detail for United Kingdom, German, France, Italy, Spain, Rest of Europe), Asia/Pacific (detail for Japan, Korea, Rest of Asia/Pacific) and Rest of World.

The report also provides background data on the surgical, disease and traumatic wound patient populations targeted by current technologies and those under development, and the current clinical practices in the management of these patients, including the dynamics among the various clinical specialties or subspecialties vying for patient population and facilitating or limiting the growth of technologies.

The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market through 2018. The report also assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

The report profiles the top companies by revenue and a reasonable selection of the most promising or otherwise noteworthy companies in the markets covered in this report, providing data on their current products, current market position and products under development.

The report is described in detail at http://www.mediligence.com/rpt/rpt-s192.htm and may be ordered for immediate download from http://www.mediligence.com/store/page50.html.

Sticky stuff: remora, mussels, geckos, crab shells, Australian burrowing frogs, spider webs, porcupine quills, sandcastle worms

It may not be obvious what links all of these creatures, but it is their all-natural adhesiveness. While we have covered these before, today Researchers at Purdue University report on the development of new glues with industrial applications (including medical) based on glues derived from, or inspired by, mussels and oysters.

The reality is that there is a very wide range of naturally occurring “bio-glues” or other adhesives (or adhesive mechanisms) that are being evaluated for their potential use as medical/surgical glues and adhesives.

(This technique of “biomimicry”, in which products are developed that exploit or replicate features in nature, is not new. Velcro, for instance, was invented in 1941 by Swiss engineer George de Mestral, who recognized a potential product in burrs, the plant seed pods covered with hooked spines that readily attach to fur, fabrics and almost any surface that has filamentous covering.)

Below is a list of organism-derived “bio-glues”, a wide range of naturally-occurring adhesives that are being investigated for their potential development as commercial adhesives, including for medical/surgical adhesion.

Most of these have at least been preliminarily investigated as to why they have such high strength, why they adhere under certain challenging conditions and other considerations. Further research and development, in some cases to an advanced degree, has been done on a number of these to actually either directly utilize these glues, modify them or develop new ones inspired by them.

MedMarket Diligence tracks the medical/surgical markets for fibrin and other sealants, glues, hemostats, tapes, vascular closure devices, and staples/sutures/clips in Report #S192. Products specifically related to closure of wounds (excluding hemostasis*) will exceed $11 billion in sales by 2018:

Screen Shot 2015-04-03 at 8.08.01 AM

*Hemostasis is covered in report #S192.

Source: MedMarket Diligence, LLC; Report #S192.

Factors Affecting Wound Market Growth Rates

Gauze dressings, bioengineered skin, alginates, negative pressure devices, cellular growth factors, hydrogels, antimicrobial dressings — all of these products (and more) represent the practice of wound management for the entire spectrum of wound types and severities.

Practice patterns, regulatory requirements, price pressures, healthcare delivery system gatekeepers, demographics, cultural sensitivities — all of these represent a sampling of the different forces that dictate the size and outlook of the markets for different wound management products in global markets.

Screen Shot 2014-05-13 at 9.20.35 AM

It’s no surprise, then, that product sales are growing (or declining) at different rates in different regions of the world, but the data is clear on this. MedMarket Diligence researched and published this data in its global wound management market Report #S249, which details the clinical practice of wound management, the products on the market and in development, the current and forecast markets for each worldwide and regionally and the competitors vying for market presence now and in the future.  Research from primary and secondary sources, the global wound market data illustrated above (which is also detailed by country) and presented in Report #S249 is a compelling read for market participants.

Shifts in Product Usage in Wound Management, 2012 to 2021

Wound management is a field and an industry in a constant state of flux. With so many different technologies involved in addressing wounds, from the chronic to the acute, with technologies from the very well established to the cutting-edge new, the balance of product utilization (and manufacturer revenues) is a constantly moving target.

Traditional wound dressings — simple gauze or other inert bandages — represent a huge existing market by virtue of their broad clinical utility and well established presence in the market (literally, centuries), while novel technologies like growth factors, which have just begun to demonstrate their potential to accelerate healing and/or solve the vexing problem of chronic wounds, have not really begun to penetrate clinical practice and generate substantial caseloads, yetBetween the extremes is a continuous range of products across the spectrum from the established to the novel.

Below is illustrated the 2012 to 2021 shift in the balance of the global wound management products market for the specific product types. The aggregate market is growing over this period at a respectable +7% CAGR, but that aggregate rate belies the individual segment rates ranging from a low of under 2% to a high of over 27%. That makes these share values all the more intriguing.

Screen Shot 2014-04-29 at 3.04.23 PM

Source: MedMarket Diligence, LLC; Report #S249.

Product Development in Surgical Glues

Surgical closure and securement products range from simple suture products to sophisticated biomaterial aids for hemostasis, sealant activity, and for adhesion prevention. Within the hemostasis field, products have the objective of rapidly achieving hemostasis and acting to seal in the presence of high pressure blood flow or air flow.

Screen Shot 2014-04-23 at 3.49.13 PMDevelopment Timelines
Natural hemostats such as gelatin, collagen and thrombin were first developed as hemostatic agents, followed by mixes and fibrin sealants. More recently, companies have introduced synthetic sealants and hemostats that accelerate the process of blood clotting and provide a stronger seal that will withstand greater pressures. These products employ various synthetic polymer chemistry systems. Glues are required to secure tissue firmly under substantial forces. In extreme cases such as musculoskeletal repair, these glues need to withstand high tension and pressure forces. Fibrin and other sealants are not strong enough for these applications and have been used as adjuncts to sutures and staples. Cyanoacrylate glues have sufficient strength for most procedures but are not yet cleared for use in the majority of internal applications due to toxicity concerns. They also lack sufficient flexibility for use in many procedures.

Efforts are progressing to develop new biomaterials capable of gluing tissues with high strength, low toxicity, and sufficient flexibility to avoid breakage of the bond. In addition, cyanoacrylate manufacturers are examining the possibility of improving cyanoacrylate technology to overcome the existing challenges of toxicity and brittleness. Despite this huge challenge, one or both of these two approaches are likely to establish new products in the next decade. In addition, the evidence of research work suggests it should be possible to create a glue technology that incorporates hemostatic properties to further enhance the role of this technology.

Apart from fibrin-based sealants and cyanoacrylate-based high-strength glues, there are three other main categories of closure/attachment products in use or in development at present.

Collagen and Thrombin Combination
Screen Shot 2014-04-23 at 3.54.26 PMCollagen is a major protein found in most mammals; the form of collagen that is generally used for wound sealant and closure is a white water-soluble fiber containing several key amino acids. In most sealants, collagen forms a matrix on which thrombin (but also fibrin, polyethylene glycol (PEG) polymers, or other compounds) are attached. The role of the collagen matrix is to channel blood with its various clotting proteins to the compounds attached to the matrix (thrombin, etc.), triggering a clotting cascade.

Polyethylene Glycol Polymer (PEG)
Screen Shot 2014-04-23 at 3.55.52 PMPolymers such as polyethylene glycol polymer (PEG) can absorb fluids and are the basis for products to seal and join tissues. CoSeal (Angiotech Pharmaceuticals, marketed by Baxter BioSurgery) and FocalSeal (Genzyme) are two products of this type. They are completely synthetic and offer quick sealing of the wound with the flexibility to expand and contract. Because these sealants are synthetic, they do not pose the risk of viral infection spreading from one person to another.

Albumin Cross-Linked with Glutaraldehyde
Screen Shot 2014-04-23 at 3.58.05 PMAlbumin, the protein that forms egg white, is one of the strongest natural adhesives in the market. Albumins are water-soluble and will coagulate when heated or combined with certain acids. When combined with glutaraldehyde, albumin forms a strong adhesive for internal surgery. The albumin/glutaraldehyde compound forms a cross-link with the tissues to be bonded that can even be stronger than the underlying tissues. In fact, the compound has been shown to withstand pressures of 500 mm–800 mm of mercury, which is more than four times normal human blood pressure.

CryoLife’s BioGlue is a widely used albumin/glutaraldehyde glue. It begins to set within 20–30 seconds of application and reaches its ultimate bonding strength within two minutes.

It is unlikely that any one formulation of tissue glue will be adequate for all applications. For example, fixing fragments of bone after significant bone trauma is likely to require an adhesive with a different modulus and strength to that required for adherence of pericardium during cardiovascular surgery. It is also likely that the sealant and hemostatic properties of these two products will need to be different. For example, to stick pericardial tissues together, the surgeon will be concerned with avoiding surgical adhesions and excessive fibrosis that might lead to problems during revision surgery. In the example of bone repair, rapid rehabilitation and avoidance of non-unions during fracture healing is a major challenge: this would suggest looking for a glue that encourages osteoblast activity and does not form an impenetrable barrier for cellular in- growth, but which can also tolerate the static and dynamic forces put upon bone.

Recently, new technologies have appeared on the market to address the need for adhesion prevention. These products have been formulated to be approvable by the FDA through device regulation routes; thus, in addition to providing a physical barrier, these products also may have some subsidiary active mechanism to achieve their objective.

Delivery Systems

Screen Shot 2014-04-23 at 4.01.16 PM
Source: CryoLife

In parallel with new products, in several instances new delivery systems have had to be developed. Surgeons also experiment with these products in an effort to produce superior results. A surgeon may, for example, mix a sealant with a few ml of saline to gain greater control over product application. Development of these delivery systems may be driven by several factors, such as: to improve the speed and ease of surgical procedures; to facilitate complex procedures that would otherwise be less successful; to better access a particular tissue; or to avoid premature mixing of two components, thus providing better control of the gluing process. New delivery systems have evolved to spray liquid hemostat solutions such as thrombin onto surgical sites to improve speed of hemostasis. Fibrin sealant is supplied as two powders that need to be solubilized and then mixed immediately prior to application to the surgical site. This has led to the development of a number of sophisticated medical delivery devices, and companies like Baxter aredeveloping single component systems that are already solubilized for immediate use in the surgical theater.

Cyanoacrylate adhesive for surgical closure is a topical-only treatment that eventually sloughs off the top surface of the wound. The product is applied to the surface of the skin to form a glue film that secures apposition of the cut edges of the incision. Currently, the cyanoacrylate is supplied in a device that aids the curing of the adhesive and ensures its safe handling and application.

Several fairly sophisticated delivery systems for new sealant and glue products have been developed or are currently under development. As new procedures are developed for cyanoacrylate and new glues, new devices will be required to aid the procedure. The devices will contribute an increasing proportion of the value associated with the gluing process.

Sophisticated surgical instruments are being developed to facilitate the application in each new indication for new high-strength glue products. High-strength glues are increasingly being utilized to repair vascular joints in coronary bypass operations. Customized instrumentation is designed to hold vessels in place and facilitate the application of exact amounts of adhesive and to avoid subsequent delays from leakage, or imperfect integration of the grafted tissues.


Source: MedMarket Diligence, LLC; Report #S190, “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2010-2017.”

Opportunities for med/surg sealants, glues, hemostats driven by type of clinical benefit, competition

Advanced products for the closure, sealing, hemostasis and other endpoints for medical and surgical wounds generate varying degrees of clinical benefit based on the manner and extent to which they enable management of different wound types.  Degrees range from the acute need end of “important and enabling” to the less clinically necessary “aesthetic and perceived benefits”:

  • Important and enabling: Important to prevent excessive bleeding and transfusion, to ensure safe procedure, and to avoid mortality and to avoid complications associated with excessive bleeding and loss of blood.
  • Improved clinical outcome: Reduces morbidity due to improved procedure, reduced surgery time, and prevention of complications such as fibrosis, post-surgical adhesion formation, and infection (includes adjunct to minimally invasive surgery).
  • Cost-effective and time-saving: Immediate reduction in surgical treatment time and follow-up treatments.
  • Aesthetic and perceived benefits: Selection is driven by aesthetic and perceived benefits, resulting in one product being favored over a number of medically equivalent treatments.

These benefits are clearly different on a clinical specialty-by-specialty basis.  The numbers of targeted or prospective procedures also vary considerably by specialty. As a result, wound closure and securement products have the following categorized potential use worldwide:

Source: “Surgical Procedures with Potential for the Use of Hemostats, Sealants, Glues and Adhesion Prevention Products, Worldwide “; Report #S190.